Maria L. Molas
Bellaterra, CT 08193, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
AAV-mediated FGF21 gene therapy promotes health span extension by whole-body tissue-specific adaptations.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 11, 2025
Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 01, 2024
Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal.
Journal: Molecular therapy. Methods & clinical development
Published: March 16, 2021
Vitamin D Receptor Overexpression in β-Cells Ameliorates Diabetes in Mice.
Journal: Diabetes
Published: August 02, 2019
Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC.
Journal: Disease models & mechanisms
Published: February 24, 2016
ALOX5AP Overexpression in Adipose Tissue Leads to LXA4 Production and Protection Against Diet-Induced Obesity and Insulin Resistance.
Journal: Diabetes
Published: January 08, 2016
Insulin-like Growth Factor 2 Overexpression Induces β-Cell Dysfunction and Increases Beta-cell Susceptibility to Damage.
Journal: The Journal of biological chemistry
Published: February 03, 2015
Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.
Journal: Human molecular genetics
Published: December 20, 2014
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.
Journal: The Journal of clinical investigation
Published: September 07, 2012
A role for oxalic acid generation in ozone-induced signallization in Arabidopis cells.
Journal: Plant, cell & environment
Published: August 18, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026